Recente en toekomstige behandelingen bij covid-19

Marloes Dankers; H Marjorie J M G Nelissen-Vrancken; Marjolein Y Berger; Marc J M Bonten; Joop M A van Gerven; Peter W A Kunst; Majon Muller; Marcel G M Olde Rikkert; Frits R Rosendaal

Recente en toekomstige behandelingen bij covid-19

Translated title of the contribution: Current and future therapeutic options for COVID-19

Marloes Dankers
, H Marjorie J M G Nelissen-Vrancken
, Marjolein Y Berger
, Marc J M Bonten
, Joop M A van Gerven
, Peter W A Kunst
, Majon Muller
, Marcel G M Olde Rikkert
, Frits R Rosendaal

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

Translated title of the contribution	Current and future therapeutic options for COVID-19
Original language	Dutch
Article number	D6675
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	166
Publication status	Published - 21 Jul 2022

Keywords

Adrenal Cortex Hormones
Anti-Inflammatory Agents/therapeutic use
Antiviral Agents/therapeutic use
COVID-19 Drug Treatment
Guanosine Monophosphate/analogs & derivatives
Humans
Phosphoramides
Recombinant Fusion Proteins
SARS-CoV-2

Access to Document

https://www.ntvg.nl/artikelen/recente-en-toekomstige-behandelingen-bij-covid-19

Cite this

Dankers, M., Nelissen-Vrancken, H. M. J. M. G., Berger, M. Y., Bonten, M. J. M., van Gerven, J. M. A., Kunst, P. W. A., Muller, M., Olde Rikkert, M. G. M., & Rosendaal, F. R. (2022). Recente en toekomstige behandelingen bij covid-19. Nederlands Tijdschrift voor Geneeskunde, 166, Article D6675. https://www.ntvg.nl/artikelen/recente-en-toekomstige-behandelingen-bij-covid-19

@article{b75092799c2846cf834edea082bccfd7,

title = "Recente en toekomstige behandelingen bij covid-19",

abstract = "The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.",

keywords = "Adrenal Cortex Hormones, Anti-Inflammatory Agents/therapeutic use, Antiviral Agents/therapeutic use, COVID-19 Drug Treatment, Guanosine Monophosphate/analogs \& derivatives, Humans, Phosphoramides, Recombinant Fusion Proteins, SARS-CoV-2",

author = "Marloes Dankers and Nelissen-Vrancken, \{H Marjorie J M G\} and Berger, \{Marjolein Y\} and Bonten, \{Marc J M\} and \{van Gerven\}, \{Joop M A\} and Kunst, \{Peter W A\} and Majon Muller and \{Olde Rikkert\}, \{Marcel G M\} and Rosendaal, \{Frits R\}",

year = "2022",

month = jul,

day = "21",

language = "Dutch",

volume = "166",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

}

TY - JOUR

T1 - Recente en toekomstige behandelingen bij covid-19

AU - Dankers, Marloes

AU - Nelissen-Vrancken, H Marjorie J M G

AU - Berger, Marjolein Y

AU - Bonten, Marc J M

AU - van Gerven, Joop M A

AU - Kunst, Peter W A

AU - Muller, Majon

AU - Olde Rikkert, Marcel G M

AU - Rosendaal, Frits R

PY - 2022/7/21

Y1 - 2022/7/21

N2 - The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

AB - The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

KW - Adrenal Cortex Hormones

KW - Anti-Inflammatory Agents/therapeutic use

KW - Antiviral Agents/therapeutic use

KW - COVID-19 Drug Treatment

KW - Guanosine Monophosphate/analogs & derivatives

KW - Humans

KW - Phosphoramides

KW - Recombinant Fusion Proteins

KW - SARS-CoV-2

M3 - Article

C2 - 36036702

SN - 0028-2162

VL - 166

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

M1 - D6675

ER -

Recente en toekomstige behandelingen bij covid-19

Abstract

Keywords

Access to Document

Fingerprint

Cite this